{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:00:04Z","timestamp":1770231604144,"version":"3.49.0"},"reference-count":63,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K007017\/1"],"award-info":[{"award-number":["MR\/K007017\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>The aims of the current review were to compare the efficacy of monotherapy with bendroflumethiazide <jats:italic>vs<\/jats:italic>. indapamide on mortality, cardiovascular outcomes, blood pressure, need for intensification of treatment and treatment withdrawal. Two authors independently screened the results of a literature search, assessed the risk of bias and extracted relevant data. Randomized clinical trials of hypertensive patients of at least a 1\u2010year duration were included. When there was disagreement, a third reviewer was consulted. Risk ratio (RR) and mean differences were used as measures of effect. Two trials comparing bendroflumethiazide against placebo, one comparing indapamide with placebo and three of short duration directly comparing indapamide and Bendroflumethiazide, were included. No statistically significant difference was found between indapamide and bendroflumethiazide for all deaths [RR 0.82; 95% confidence interval (CI) 0.57, 1.18], cardiovascular deaths (RR 0.82; 95% CI 0.55, 1.20), noncardiovascular deaths (0.81; 95% CI 0.54, 1.22), coronary events (RR 0.73; 95% CI 0.30, 1.79) or all cardiovascular events (RR 0.89; 95% CI 0.67, 1.18). Indapamide performed worse for stroke (RR 2.21; 95% CI 1.19, 4.11), even though a reduction in RR compared with placebo was observed in both groups. There was no statistically or clinically significant difference between indapamide and bendroflumethiazide in blood pressure reduction (mean absolute difference &lt;1\u00a0mmHg). The present review highlights a lack of studies to answer the review question but also a lack of evidence of superiority of one drug over the other. Therefore, there is a clear need for new studies directly comparing the effect of these drugs on the outcomes of interest.<\/jats:p>","DOI":"10.1111\/bcp.13787","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T17:15:26Z","timestamp":1539364526000},"page":"285-303","source":"Crossref","is-referenced-by-count":14,"title":["The effect of indapamide <i>vs<\/i>. bendroflumethiazide for primary hypertension: a systematic review"],"prefix":"10.1111","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9392-0812","authenticated-orcid":false,"given":"Tatiana V.","family":"Macfarlane","sequence":"first","affiliation":[{"name":"Medicines Monitoring Unit (MEMO), School of Medicine University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pigazzani","sequence":"additional","affiliation":[{"name":"Medicines Monitoring Unit (MEMO), School of Medicine University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.V.","family":"Flynn","sequence":"additional","affiliation":[{"name":"Medicines Monitoring Unit (MEMO), School of Medicine University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Medicines Monitoring Unit (MEMO), School of Medicine University of Dundee  Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"World Health Organization. Global Health Observatory (GHO) data. Available athttp:\/\/www.who.int\/gho\/ncd\/risk_factors\/blood_pressure_prevalence_text\/en\/(last accessed 18 September 2017)."},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"28","author":"Chobanian AV","year":"2003","journal-title":"JAMA"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0907219"},{"key":"e_1_2_6_5_1","first-page":"CD001841","article-title":"First\u2010line drugs for hypertension","volume":"4","author":"Wright JM","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_6_1","first-page":"CD010316","article-title":"First\u2010line combination therapy versus first\u2010line monotherapy for primary hypertension","volume":"1","author":"Garj\u00f3n J","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aogh.2016.02.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.879118"},{"key":"e_1_2_6_9_1","unstructured":"National Institute for Health and Clinical Excellence (NICE).Hypertension in adults: diagnosis and management. Clinical guideline August 2011. Available athttps:\/\/www.nice.org.uk\/guidance\/cg127(last accessed 13 April 2017)."},{"key":"e_1_2_6_10_1","unstructured":"National Institute for Health and Clinical Excellence (NICE).Hypertension: evidence update March 2013. A summary of selected new evidence relevant to NICE clinical guideline 127 \u2018clinical management of primary hypertension in adults\u2019;2011. Evidence update 32. March 2013. Available athttps:\/\/www.nice.org.uk\/guidance\/cg127\/evidence\/evidence-update-248584429.%20Accessed%202017(last accessed 13 April 2017)."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d8218"},{"key":"e_1_2_6_12_1","article-title":"Blood pressure\u2010lowering efficacy of monotherapy with thiazide diuretics for primary hypertension","volume":"5","author":"Musini VM","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.190637"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-1754"},{"key":"e_1_2_6_15_1","article-title":"Pharmacotherapy for hypertension in adults aged 18 to 59 years","volume":"16","author":"Musini VM","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03306-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2534"},{"key":"e_1_2_6_18_1","article-title":"Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals","volume":"3","author":"Taverny G","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_19_1","unstructured":"NHS National Institute for Health Research. PROSPERO.International prospective register of systematic reviews. Available athttps:\/\/www.crd.york.ac.uk\/PROSPERO\/(last accessed 14 November 2018)."},{"key":"e_1_2_6_20_1","unstructured":"The preferred reporting items for systematic reviews and meta\u2010analyses (PRISMA) statement. Available athttp:\/\/prisma\u2010statement.org\/(last accessed 11 August 2017)."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_6_22_1","article-title":"Pharmacotherapy for hypertension in the elderly","volume":"4","author":"Musini VM","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1401400106"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654"},{"key":"e_1_2_6_25_1","volume-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach","author":"Sch\u00fcnemann H","year":"2013"},{"key":"e_1_2_6_26_1","unstructured":"GRADEpro GDT: GRADEpro guideline development tool [software]. McMaster University 2015 (developed by Evidence Prime Inc.). Available athttps:\/\/gradepro.org\/(last accessed 14 November 2018)."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200312000-00030"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004576"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198710000-00009"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5877.434"},{"key":"e_1_2_6_31_1","first-page":"16","article-title":"Results of MRC (UK) trial of drug therapy for mild hypertension","volume":"10","author":"Peart S","year":"1987","journal-title":"Clin Invest Med"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6488.97"},{"key":"e_1_2_6_33_1","first-page":"539","article-title":"Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension","volume":"2","author":"Peart WS","year":"1981","journal-title":"Lancet"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.59.3.364"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6553.988"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6074.1437"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6636.1565"},{"key":"e_1_2_6_38_1","first-page":"563s","article-title":"Medical Research Council's treatment trial for mild hypertension: an interim report","volume":"3","author":"Miall WE","year":"1976","journal-title":"Clin Sci Mol Med Suppl"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1987.tb03012.x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801369"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118030-00001"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000195"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000901"},{"key":"e_1_2_6_44_1","first-page":"631","article-title":"The Hypertension in the Very Elderly Trial (HYVET)","volume":"8","author":"Bulpitt CJ","year":"1994","journal-title":"J Hum Hypertens"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199405030-00003"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01325.x"},{"issue":"2","key":"e_1_2_6_47_1","first-page":"51","article-title":"A comparative study of the efficacy of indapamide and bendrofluazide given in combination with atenolol","volume":"57","author":"Zacharias FJ","year":"1981","journal-title":"Postgrad Med J"},{"key":"e_1_2_6_48_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/01.fjc.0000211707.64993.85","article-title":"Comparison of the effect of diuretics on carotid blood flow in stroke patients","volume":"47","author":"Milia P","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_6_49_1","unstructured":"EBM DataLab University of Oxford 2018. Available athttps:\/\/openprescribing.net\/(last accessed 2 September 2018)."},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13205"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.03.005"},{"key":"e_1_2_6_52_1","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","author":"Whelton PK","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_6_53_1","first-page":"579","article-title":"Writing group of 2010 Chinese Guidelines for the Management of Hypertension: 2010 Chinese guidelines for the management of hypertension","volume":"39","author":"Liu LS","year":"2011","journal-title":"Chin J Cardiol"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001039"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000076"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1147"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-1-41"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nepr.2011.10.007"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.01.004"},{"key":"e_1_2_6_61_1","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP\u00ae). Available athttp:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=25524(last accessed 14 November 2018)."},{"key":"e_1_2_6_62_1","unstructured":"Clinical Practice Research Datalink. Available athttps:\/\/www.cprd.com\/home\/(last accessed 14 November 2018)."},{"key":"e_1_2_6_63_1","unstructured":"Evaluating Diuretics in Normal Care (EVIDENCE) \u2013 a cluster randomised evaluation of hypertension prescribing policy. Available athttp:\/\/www.isrctn.com\/ISRCTN46635087(last accessed 16 April 2018)."},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:13:30Z","timestamp":1694340810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/bcp.13787"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13787","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]}}}